Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effects of Curcumin Supplementation on Inflammatory Markers in Systemic Lupus Erythematosus Patients: A Randomized Placebo-Controlled Trial Publisher Pubmed



Sedighi S1 ; Faramarzipalangar Z2 ; Mohammadi E3, 4 ; Aghamohammadi V3 ; Bahnemiri MG5 ; Mohammadi K6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Golestan Rheumatology Research Center, Golestan University of Medical Science, Gorgan, Iran
  2. 2. Department of Nutrition, School of Agricultural Sciences and Veterinary Medicine, University of Padua, Padua, Italy
  3. 3. Department of Nutrition, Khalkhal University of Medical Sciences, Khalkhal, Iran
  4. 4. Department of Nutritional Sciences, School of Health, Mazandaran University of Medical Sciences, Sari, Iran
  5. 5. Department of Laboratory Sciences, Sari Branch, Islamic Azad University, Sari, Iran
  6. 6. Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: European Journal of Nutrition Published:2025


Abstract

Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement. This study was designed to examine the effects of curcumin, a polyphenolic compound isolated from turmeric rhizomes, on inflammatory markers in SLE patients. Methods: Seventy 18–60 years old SLE patients were recruited in this randomized triple-blinded placebo-controlled trial, and 62 completed the study. Curcumin group received 1000 mg curcumin daily and the placebo group received placebo capsules for 10 weeks. Dietary intakes and serum levels of complement C3 and C4, complement hemolytic 50%, rheumatoid factor, anti-double stranded DNA (anti-ds DNA), erythrocyte sedimentation rate, high-sensitivity C-reactive protein, interlukine-6 (IL-6) and tumor necrosis factor-α were assessed before and after intervention period. Results: Curcumin supplementation caused a significant reduction in anti-ds DNA and IL-6 levels at the end of the trial in comparison with baseline (52.57 ± 40.21 vs. 43.27 ± 28.34, p = 0.014 and 127.11 ± 76.63 vs. 101.49 ± 59.08, p = 0.002, respectively). Analysis of covariance which was adjusted for confounding variables also revealed that anti-ds DNA and IL-6 levels decreased significantly in curcumin group compared to placebo group by the end of the intervention period (change:-9.30 ± 19.59 vs. -2.55 ± 17.55, p = 0.018 and − 25.62 ± 42.33 vs. -7.34 ± 34.32, p = 0.043, respectively). No significant changes were observed in levels of other variables during the study (p > 0.05). Conclusion: Curcumin as an effective and safe adjuvant therapy, ameliorated the autoimmune activity and inflammation in SLE patients via reducing anti-ds DNA and IL-6 levels. Clinical trial registration: irct.behdasht.gov.ir, identifier: IRCT20210425051077N1. © Springer-Verlag GmbH Germany, part of Springer Nature 2024.
Related Docs
1. The Potential Neuroprotective Roles of Olive Leaf Extract in an Epilepsy Rat Model Induced by Kainic Acid, Research in Pharmaceutical Sciences (2021)
2. Administration of Dietary Antioxidants for Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials, Complementary Therapies in Medicine (2021)